The Heart Protection Study: expanding the boundaries for high-risk coronary disease prevention

Clinical trial evidence strongly favors aggressive risk factor modification in the prevention of coronary artery disease (CAD). The latest landmark trial of therapy using a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) is the Heart Protection Study (HPS) of simvastatin versus pl...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2003-07, Vol.92 (1), p.3-9
Main Authors: Farmer, John A, Gotto, Antonio M
Format: Article
Language:English
Subjects:
Cardiovascular disease
Clinical trials
Clinical Trials as Topic
Coronary Disease - epidemiology
Coronary Disease - prevention & control
Drug therapy
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Hyperlipidemias - drug therapy
Hyperlipidemias - epidemiology
Hypolipidemic Agents - therapeutic use
Prevention
Risk Factors
Risk Reduction Behavior
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clinical trial evidence strongly favors aggressive risk factor modification in the prevention of coronary artery disease (CAD). The latest landmark trial of therapy using a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) is the Heart Protection Study (HPS) of simvastatin versus placebo in a cohort of patients at high risk for CAD. The HPS reported a number of highly significant reductions in the risk for major vascular events with treatment. It also provides new insights into the effects of statin therapy in patient subgroups, such as the elderly, women, and those with noncoronary vascular disease. These data are likely to have an important influence on the future of cardiovascular disease prevention.
ISSN:0002-9149
1879-1913
DOI:10.1016/S0002-9149(03)00503-4